These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1595 related articles for article (PubMed ID: 34735018)

  • 1. COVID-19 Therapeutics and Vaccines: A Race to Save Lives.
    Bebenek I; Bannister R; Dubinion J; Fortin M; Liu M; Motter AL; Rohde CM; Wrzesinski C
    Toxicol Sci; 2022 Jan; 185(2):119-127. PubMed ID: 34735018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
    Levey NH; Forrest AD; Spielman DW; Easley KA; Dude CM; Badell ML
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100673. PubMed ID: 35671984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
    Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
    Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
    Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: The status and perspectives in delivery points of view.
    Chung JY; Thone MN; Kwon YJ
    Adv Drug Deliv Rev; 2021 Mar; 170():1-25. PubMed ID: 33359141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan.
    Terakawa K; Katagiri D; Shimada K; Sato L; Takano H
    CEN Case Rep; 2022 Aug; 11(3):328-332. PubMed ID: 35000134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
    Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
    Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
    Tuccori M; Convertino I; Ferraro S; Cappello E; Valdiserra G; de Luca G; Franchini M; Focosi D
    Expert Opin Drug Discov; 2022 Jun; 17(6):531-546. PubMed ID: 35361043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
    Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
    J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
    Dooling K; Gargano JW; Moulia D; Wallace M; Rosenblum HG; Blain AE; Hadler SC; Plumb ID; Moline H; Gerstein J; Collins JP; Godfrey M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1344-1348. PubMed ID: 34555007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
    Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
    J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
    [No Abstract]   [Full Text] [Related]  

  • 19. Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail.
    Lehman A; Muñiz VA; Chaney R; Pimentel J; Mattila J; Lawrence S
    Curr Opin Biotechnol; 2022 Aug; 76():102715. PubMed ID: 35447504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.